Even though the risk was more than doubled, the overall risk of developing wet AMD was very low: only 93 patients taking GLP-1 medications developed wet AMD after three years among over 46,000 patients in the study
Now, researchers at Aarhus University's Department of Biomedicine have identified a possible new direction for future therapies involving GLP-1, the hormone targeted by popular weight loss medications such as Wegovy
The program also offers personalized dosing for GLP-1 medications like Semaglutide, Tirzepatide, Mounjaro, Zepbound, Wegovy, and Ozempic, based on how your body responds to the treatment
Your ideal target depends on your age, weight, activity level, and overall health, so the best number is the one your provider sets with you
Experts dont know whether people taking GLP-1s lose more muscle, less or just the right amount relative to other forms of weight loss or even if whats lost is healthy muscle tissue
Meanwhile, Wegovy is facing tough competition from Eli Lilly's weight-loss therapy Zepbound (tirzepatide), which outperformed its rival in the head-to-head SURMOUNT-5 trial